翻訳と辞書 |
Romosozumab
Romosozumab (AMG 785) is a humanized monoclonal antibody that targets sclerostin for the treatment of osteoporosis.〔(【引用サイトリンク】publisher=American Medical Association )〕 Romosozumab was originally discovered by Celltech (now owned by UCB).〔Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003 Dec 1;22(23):6267-76.〕 Celltech entered in a partnership with Amgen in 2002 for the product's development.〔Celltech group Annual Report and Accounts 2002〕 Romosozumab is of interest because of sclerostin's specificity to bone. Its use has increased bone growth in preclinical trials in osteoporotic rats and monkeys. In a Phase I study, a single dose of Romosozumab increased bone density in the hip and spine in healthy men and postmenopausal women and the drug was well tolerated. In a Phase II trial, one year of Romosozumab treatment in osteoporotic women increased bone density more than bisphosphonate and teriparatide treatment; it had mild injection side effects. , Phase 3 clinical trials are recruiting patients.〔ClinicalTrials.gov: (Romosozumab )〕 == References ==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Romosozumab」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|